We are live on ! Find out more
IBIO icon

iBio
IBIO

43 hedge funds and large institutions have $4.97M invested in iBio in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more call options, than puts

Call options by funds: $85K | Put options by funds: $73K

0% more ownership

Funds ownership: 0.03% → 0.03% (+0%)

19% less funds holding

Funds holding: 53 → 43 (-10)

35% less capital invested

Capital invested by funds: $7.63M → $4.97M (-$2.66M)

36% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 11

64% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 14

Holders
43
Holders Change
-10
Holders Change %
-18.87%
% of All Funds
0.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
11
Closed
14
Calls
$85K
Puts
$73K
Net Calls
+$12K
Net Calls Change
-$21K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$782K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$228K
3
N
Natixis
France
+$53.1K
4
Charles Schwab
Charles Schwab
California
+$49.8K
5
Renaissance Technologies
Renaissance Technologies
New York
+$37.6K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$602K
2
Citadel Advisors
Citadel Advisors
Florida
-$141K
3
Goldman Sachs
Goldman Sachs
New York
-$78K
4
Morgan Stanley
Morgan Stanley
New York
-$74.9K
5
E
Ergoteles
New York
-$53.3K

IBIO Hedge Fund Activity: Q3 2022 in Review

43 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q3 2022, worth a combined $4.97M — down 35% from $7.63M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of IBIO and 5 opened new positions — a net loss of 9 holders — while 11 trimmed existing stakes and 7 added.

The largest buyer was BlackRock, adding an estimated $782K. The largest seller was Millennium Management, cutting an estimated $602K.

  • 43 institutional investors held iBio (IBIO) as of Q3 2022, down from 53 in Q2 2022.
  • Funds reported $4.97M of iBio stock for Q3 2022, down 35% quarter-over-quarter.
  • 5 funds opened new iBio positions in Q3 2022 and 14 closed out, a net change of -9 holders.
  • The largest iBio buyer in Q3 2022 was BlackRock, an estimated $782K added.
  • The largest iBio seller in Q3 2022 was Millennium Management, an estimated $602K sold.

Based on aggregated 13F filings for Q3 2022.